November 1, 2009
In this interview, Michael B. Chancellor, MD, discusses using botulinum toxin for treating overactive bladder, BPH, interstitial cystitis, and other conditions.
 |
November 1, 2009
By:Wayne Kuznar
A study shows that most patients with nocturia have nocturnal polyuria, which is consistent with other studies showing that overproduction of urine at night is a major contributory factor to nocturia in about 80% of patients.
|
November 1, 2009
By:Shlomo Raz, MD, Ja-Hong Kim, MD
Drs. Shlomo Raz and Ja-Hong Kim discuss recent advances in the treatment of stress incontinence.
|
November 1, 2009
By:Penny Allen
Nerve growth factor levels in urine could prove a useful biomarker for interstitial cystitis/painful bladder syndrome and neurogenic overactive bladder.
|
November 1, 2009
By:Penny Allen
Alpha-blockers, tricyclic antidepressants, or both can improve compliance, lower pressures at bladder capacity, and improve reflux, incontinence, and detrusor overactivity in neurogenic bladder patients.
|
November 1, 2009
By:Philip M. Hanno, MD, MPH
In this podcast, Dr. Phil Hanno interviews Dr. Michael Chancellor on the potential role of botulinum toxin in urology.
|
November 1, 2009
By:Mac Overmyer
Over the course of a decade, the therapeutic pendulum in treating urinary incontinence in women swung dramatically from needle suspension and anterior urethropexy to collagen injections and back again to suspension procedures with no sound clinical trials driving the move to either approach.
|
August 1, 2009
By:Leslie M. Rickey, MD, MPH
It's not clear yet whether transvaginal mesh offers superior anatomic or symptomatic outcomes compared to traditional apical suspension repairs.
|
August 1, 2009
By:Wayne Kuznar
Most women who undergo sacral neuromodulation for refractory overactive bladder report concomitant bowel symptoms when asked.
|
| 
Practice Tools
Brings you the latest news and information twice each month.